HEALTH PROFESSIONAL · SOURCE READING
Treatment of Childhood Esthesioneuroblastoma
Source: Childhood Esthesioneuroblastoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: August 7, 2024 · Captured 2026-09-09.
Selected source text with whitespace normalised. This Triangle page is not an NCI PDQ summary.
The use of multimodal therapy optimizes the chances for survival, with more than 70% of children expected to survive 5 or more years after initial diagnosis.[1-5] Neuromeningeal progression is the most common type of treatment failure.[5,6][Level of evidence C1]
Source links and citations
Treatment options according to Kadish stage include the following:[7]
Source links and citations
Kadish stage A: Surgery alone with clear margins. Adjuvant radiation therapy is indicated in patients with close and positive margins or with residual disease.
Kadish stage B: Surgery followed by adjuvant radiation therapy. The role of adjuvant chemotherapy is controversial.
Kadish stage C: Neoadjuvant approach with chemotherapy, radiation therapy, or concurrent chemoradiation therapy followed by surgery.
Kadish stage D: Systemic chemotherapy and radiation therapy to local and metastatic sites.
The mainstay of treatment is surgery and radiation therapy. However, esthesioneuroblastoma is a chemosensitive neoplasm, and the use of neoadjuvant chemotherapy can facilitate resection.[5,7-9] Endoscopic sinus surgery offers short-term outcomes similar to open craniofacial resection.[10]; [11][Level of evidence C2] Other techniques such as stereotactic radiosurgery and proton-beam therapy (charged-particle radiation therapy) may also play a role in the management of this tumor.[3,12,13]
Source links and citations
Routine neck dissection and nodal exploration are not indicated in the absence of clinical or radiological evidence of disease.[14] Management of cervical lymph node metastases has been addressed in a review article.[14]
Reports have indicated promising results with the increased use of resection and neoadjuvant or adjuvant chemotherapy in patients with advanced-stage disease.[2,5,15-17]; [18][Level of evidence C1] Chemotherapy regimens that have been used with efficacy include the following:
Vincristine, dactinomycin, and cyclophosphamide with or without doxorubicin.
Ifosfamide and etoposide.
Cisplatin plus etoposide or doxorubicin.[2]
Source links and citations
Vincristine, doxorubicin, and cyclophosphamide.[21]
Source links and citations
Irinotecan plus docetaxel.[22][Level of evidence C1]
Source links and citations
Publication references
Read the original reference and check its publication notices.
- PubMed 12218598 · Original source
- PubMed 15484215 · Original source
- PubMed 15806328 · Original source
- PubMed 15925980 · Original source
- PubMed 18189294 · Original source
- PubMed 18633576 · Original source
- PubMed 19205593 · Original source
- PubMed 20706843 · Original source
- PubMed 22261850 · Original source
- PubMed 22443159 · Original source
- PubMed 22995757 · Original source
- PubMed 24390450 · Original source
- PubMed 25820437 · Original source
- PubMed 26380824 · Original source
- PubMed 26514449 · Original source
- PubMed 31930719 · Original source
- PubMed 32793498 · Original source
- PubMed 38018357 · Original source
Preserved source evidence · Not medical advice
Triangle